Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Certara (CERT)
NASDAQ:CERT
Certara (CERT) Stock Price & Analysis
179 Followers
CERT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.81 - $24.70
Previous Close$16.73
Volume421.45K
Average Volume (3M)557.01K
Market Cap
$2.67B
Enterprise Value$2.74B
Total Cash (Recent Filing)$234.95M
Total Debt (Recent Filing)$298.19M
Price to Earnings (P/E)-48.1
Beta1.57
Next Earnings
May 07, 2024EPS Estimate
$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding159,855,345
10 Day Avg. Volume481,502
30 Day Avg. Volume557,008
Standard Deviation0.17
R-Squared0.23
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-16.50
Price to Sales (P/S)30.39
Price to Cash Flow (P/CF)27.70
P/FCF Ratio10.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.73
Enterprise Value/Gross Profit12.83
Enterprise Value/Ebitda862.24
Forecast
1Y Price Target
$19.10Price Target Upside16.11% Upside
Rating ConsensusHold
Number of Analyst Covering6
Certara News
Bulls Say, Bears Say
Bulls Say
Industry ImpactOver 90% of FDA approvals over the past decade have originated from customers using Certara's software and services, highlighting the company's impactful presence in the drug development industry.
Market OpportunityCertara is a leading provider of model-informed drug development software and services with an addressable market exceeding $14B, indicating a significant growth opportunity.
Regulatory AdoptionCertara's software is adopted by 23 global regulatory agencies, providing important validation and reputational advantages.
Bears Say
Clinical Trials And Market ActivityAnalyst expresses caution due to decelerating clinical trial initiations and modest biopharma capital markets activity.
Financial PerformanceThe company's topline growth is below the expected mid-teens, contributing to its valuation being under historical averages.
Macroeconomic FactorsCertara is facing challenges from macroeconomic factors such as lower biopharma spend and a tougher capital markets environment.
---
Ownership Overview
4.15% Insiders
27.56% Mutual Funds
19.18% Other Institutional Investors
49.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CERT FAQ
What was Certara’s price range in the past 12 months?
Certara lowest stock price was $11.81 and its highest was $24.70 in the past 12 months.
What is Certara’s market cap?
Currently, no data Available
When is Certara’s upcoming earnings report date?
Certara’s upcoming earnings report date is May 07, 2024 which is in 12 days.
How were Certara’s earnings last quarter?
Certara released its earnings results on Feb 29, 2024. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.109 by -$0.019.
Is Certara overvalued?
According to Wall Street analysts Certara’s price is currently Undervalued.
Does Certara pay dividends?
Certara does not currently pay dividends.
What is Certara’s EPS estimate?
Certara’s EPS estimate is $0.1.
How many shares outstanding does Certara have?
Certara has 159,855,350 shares outstanding.
What happened to Certara’s price movement after its last earnings report?
Certara reported an EPS of $0.09 in its last earnings report, missing expectations of $0.109. Following the earnings report the stock price went up 8.412%.
Which hedge fund is a major shareholder of Certara?
Among the largest hedge funds holding Certara’s share is Bridgewater Associates, LP. It holds Certara’s shares valued at 4M.
---
Certara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.10 (16.11% Upside)
$19.10 (16.11% Upside)
Blogger Sentiment
Bullish
CERT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 43.3%
Last 30 Days ▲ 43.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.46%
12-Months-Change
Fundamentals
Return on Equity
-5.21%
Trailing 12-Months
Asset Growth
-0.62%
Trailing 12-Months
Company Description
Certara
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
---
CERT Company Deck
---
CERT Earnings Call
Q4 2024
0:00 / 0:00
---
CERT Stock 12 Months Forecast
Average Price Target
$19.10
▲(16.11% Upside)
Technical Analysis
Best Analysts Covering CERT
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-7.40%
reiterated a buy rating 8 months ago
Copying Gaurav Goparaju's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -7.40% per trade.
---